Introduction: Mind-body intervention (MBI) serves as a supportive aid in oncology. We hypothesized that MBI could impact the progression of chronic lymphocytic leukemia (CLL) in the “watch and wait” (w&w) phase. Methods: We conducted a non-randomized, prospective controlled study between the years 2020 and 2022 on 76 treatment-naïve CLL patients in the w&w phase. Thirty-seven patients were included in the intervention arm and received MBI, while 39 patients were included in the control group. The primary and secondary endpoints were prolongation of lymphocyte doubling time (LDT) and treatment-free survival (TFS). LDT was compared at 0, 180, 360, and 540 days using paired t tests. TFS was compared between the intervention and control groups using the log-rank test. Cox proportional hazards models were used to calculate the hazard ratio (HR) and 95% confidence interval (CI) for TFS in the intervention group compared to the control, stratified by the study covariates. Results: MBI prolonged LDT at all time points, including at day 360 (median of 2.47 years; CI 1.05–3.9; p = 0.001). TFS at 18 months was longer in the intervention group compared to the control group (HR 0.23; CI 0.06–0.79, p = 0.01). Conclusions: MBI was associated with prolonged LDT and TFS in patients with CLL in the w&w phase. These results provide a basis for a larger randomized controlled trial.

1.
Chaoul
A
,
Milbury
K
,
Sood
AK
,
Prinsloo
S
,
Cohen
L
.
Mind-body practices in cancer care
.
Curr Oncol Rep
.
2014
;
16
(
12
):
417
.
2.
Eckerling
A
,
Ricon-Becker
I
,
Sorski
L
,
Sandbank
E
,
Ben-Eliyahu
S
.
Stress and cancer: mechanisms, significance and future directions
.
Nat Rev Cancer
.
2021
;
21
(
12
):
767
85
.
3.
Falcinelli
M
,
Thaker
PH
,
Lutgendorf
SK
,
Conzen
SD
,
Flaherty
RL
,
Flint
MS
.
The role of psychologic stress in cancer initiation: clinical relevance and potential molecular mechanisms
.
Cancer Res
.
2021
;
81
(
20
):
5131
40
.
4.
Liu
J
,
Chen
P
,
Wang
R
,
Yuan
Y
,
Wang
X
,
Li
C
.
Effect of Tai Chi on mononuclear cell functions in patients with non-small cell lung cancer
.
BMC Complement Altern Med
.
2015
;
15
:
3
.
5.
Moreno-Smith
M
,
Lutgendorf
SK
,
Sood
AK
.
Impact of stress on cancer metastasis
.
Future Oncol
.
2010
;
6
(
12
):
1863
81
.
6.
Smith
HR
.
Depression in cancer patients: pathogenesis, implications and treatment (Review)
.
Oncol Lett
.
2015
;
9
(
4
):
1509
14
.
7.
Spiegel
D
.
Mind matters in cancer survival
.
Psychooncology
.
2012
;
21
(
6
):
588
93
.
8.
Wang
X
,
Wang
N
,
Zhong
L
,
Wang
S
,
Zheng
Y
,
Yang
B
, et al
.
Prognostic value of depression and anxiety on breast cancer recurrence and mortality: a systematic review and meta-analysis of 282,203 patients
.
Mol Psychiatry
.
2020
;
25
(
12
):
3186
97
.
9.
Chandwani
KD
,
Ryan
JL
,
Peppone
LJ
,
Janelsins
MM
,
Sprod
LK
,
Devine
K
, et al
.
Cancer-related stress and complementary and alternative medicine: a review
.
Evid Based Complement Alternat Med
.
2012
;
2012
:
979213
.
10.
Carlson
LE
,
Beattie
TL
,
Giese-Davis
J
,
Faris
P
,
Tamagawa
R
,
Fick
LJ
, et al
.
Mindfulness-based cancer recovery and supportive-expressive therapy maintain telomere length relative to controls in distressed breast cancer survivors
.
Cancer
.
2015
;
121
(
3
):
476
84
.
11.
Mathur
MB
,
Epel
E
,
Kind
S
,
Desai
M
,
Parks
CG
,
Sandler
DP
, et al
.
Perceived stress and telomere length: a systematic review, meta-analysis, and methodologic considerations for advancing the field
.
Brain Behav Immun
.
2016
;
54
:
158
69
.
12.
Cherkin
DC
,
Herman
PM
.
Cognitive and mind-body therapies for chronic low back pain and neck pain: effectiveness and value
.
JAMA Intern Med
.
2018
;
178
(
4
):
556
7
.
13.
Dossett
ML
,
Fricchione
GL
,
Benson
H
.
A new era for mind-body medicine
.
N Engl J Med
.
2020
;
382
(
15
):
1390
1
.
14.
Mao
JJ
,
Ismaila
N
,
Bao
T
,
Barton
D
,
Ben-Arye
E
,
Garland
EL
, et al
.
Integrative medicine for pain management in oncology: society for integrative oncology-ASCO guideline
.
J Clin Oncol
.
2022
;
40
(
34
):
3998
4024
.
15.
Eichhorst
B
,
Robak
T
,
Montserrat
E
,
Ghia
P
,
Niemann
CU
,
Kater
AP
, et al
.
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
.
Ann Oncol
.
2021
;
32
(
1
):
23
33
.
16.
Hallek
M
.
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment
.
Am J Hematol
.
2019
;
94
(
11
):
1266
87
.
17.
Kwok
M
,
Oldreive
C
,
Rawstron
AC
,
Goel
A
,
Papatzikas
G
,
Jones
RE
, et al
.
Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL
.
Blood
.
2020
;
135
(
6
):
411
28
.
18.
Baumann
T
,
Moia
R
,
Gaidano
G
,
Delgado
J
,
Condoluci
A
,
Villamor
N
, et al
.
Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients
.
Leukemia
.
2021
;
35
(
8
):
2325
31
.
19.
Morabito
F
,
Tripepi
G
,
Moia
R
,
Recchia
AG
,
Boggione
P
,
Mauro
FR
, et al
.
Lymphocyte doubling time as a key prognostic factor to predict time to first treatment in early-stage chronic lymphocytic leukemia
.
Front Oncol
.
2021
;
11
:
684621
.
20.
Gonzalez-Gascon
YMI
,
Munoz-Novas
C
,
Rodriguez-Vicente
AE
,
Quijada-Álamo
M
,
Hernández-Sánchez
M
,
Pérez-Carretero
C
, et al
.
From biomarkers to models in the changing landscape of chronic lymphocytic leukemia: evolve or become extinct
.
Cancers
.
2021
;
13
(
8
):
1782
.
21.
Condoluci
A
,
Terzi di Bergamo
L
,
Langerbeins
P
,
Hoechstetter
MA
,
Herling
CD
,
De Paoli
L
, et al
.
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia
.
Blood
.
2020
;
135
(
21
):
1859
69
.
22.
Vogelstein
B
,
Kinzler
KW
.
The multistep nature of cancer
.
Trends Genet
.
1993
;
9
(
4
):
138
41
.
23.
Parsonnet
J
,
Hansen
S
,
Rodriguez
L
,
Gelb
AB
,
Warnke
RA
,
Jellum
E
, et al
.
Helicobacter pylori infection and gastric lymphoma
.
N Engl J Med
.
1994
;
330
(
18
):
1267
71
.
24.
Edwards
DJA
.
Using schema modes for case conceptualization in schema therapy: an applied clinical approach
.
Front Psychol
.
2021
;
12
:
763670
.
25.
Sportoletti
P
,
De Falco
F
,
Del Papa
B
,
Baldoni
S
,
Guarente
V
,
Marra
A
, et al
.
NK cells in chronic lymphocytic leukemia and their therapeutic implications
.
Int J Mol Sci
.
2021
;
22
(
13
):
6665
.
26.
Fayad
L
,
Keating
MJ
,
Reuben
JM
,
O’Brien
S
,
Lee
BN
,
Lerner
S
, et al
.
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome
.
Blood
.
2001
;
97
(
1
):
256
63
.
27.
Ahn
IE
,
Underbayev
C
,
Albitar
A
,
Herman
SEM
,
Tian
X
,
Maric
I
, et al
.
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
.
Blood
.
2017
;
129
(
11
):
1469
79
.
28.
Wang
Y
,
Tschautscher
MA
,
Rabe
KG
,
Call
TG
,
Leis
JF
,
Kenderian
SS
, et al
.
Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center
.
Haematologica
.
2020
;
105
(
3
):
765
73
.
29.
Ding
W
.
Richter transformation in the era of novel agents
.
Hematology Am Soc Hematol Educ Program
.
2018
;
2018
(
1
):
256
63
.
30.
Burger
JA
,
Barr
PM
,
Robak
T
,
Owen
C
,
Ghia
P
,
Tedeschi
A
, et al
.
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
.
Leukemia
.
2020
;
34
(
3
):
787
98
.
31.
Al-Sawaf
O
,
Zhang
C
,
Tandon
M
,
Sinha
A
,
Fink
AM
,
Robrecht
S
, et al
.
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
.
Lancet Oncol
.
2020
;
21
(
9
):
1188
200
.
32.
Coyne
JC
,
Tennen
H
,
Ranchor
AV
.
Positive psychology in cancer care: a story line resistant to evidence
.
Ann Behav Med
.
2010
;
39
(
1
):
35
42
.
33.
Nakaya
N
,
Bidstrup
PE
,
Saito-Nakaya
K
,
Frederiksen
K
,
Koskenvuo
M
,
Pukkala
E
, et al
.
Personality traits and cancer risk and survival based on Finnish and Swedish registry data
.
Am J Epidemiol
.
2010
;
172
(
4
):
377
85
.
34.
Chvetzoff
G
,
Tannock
IF
.
Placebo effects in oncology
.
J Natl Cancer Inst
.
2003
;
95
(
1
):
19
29
.
35.
Tavel
ME
.
The placebo effect: the good, the bad, and the ugly
.
Am J Med
.
2014
;
127
(
6
):
484
8
.
36.
Hansen
BJ
,
Meyhoff
HH
,
Nordling
J
,
Mensink
HJ
,
Mogensen
P
,
Larsen
EH
.
Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia. The ALFECH Study Group
.
Scand J Urol Nephrol
.
1996
;
30
(
5
):
373
7
.
You do not currently have access to this content.